A Randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults
Latest Information Update: 15 Dec 2021
At a glance
- Drugs AG0302-COVID19 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms AG0302-COVID19
- Sponsors AnGes
- 15 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI205419).
- 05 Nov 2021 Results presented in an AnGes Media Release.
- 01 Oct 2021 Status changed from active, no longer recruiting to completed.